Video summary

Why It’s Illegal to Call a Drug “Stroebenazoline”

Main summary

Key takeaways

Educational

Main ideas & lessons

  • You can’t just name a drug anything: Calling a drug by an arbitrary name is illegal/regulated because drug naming must prevent dangerous mix-ups and comply with strict international and national rules.
  • Drug naming requires multiple distinct names, each serving different purposes:
    • Compound (research) name: an internal identifier used during development.
    • Generic (international) name: the universally applicable name for the active ingredient.
    • Proprietary (brand) name: the brand name for a specific marketed formulation.
  • Names must reduce medication errors:
    • Similar-looking or similar-sounding names can cause real-world harm. The video cites WHO-style consequences: deaths and injuries from lookalike/soundalike medications.
  • Naming is a rule-based approval process involving:
    • Multiple bodies (including the WHO and the U.S. system via the USAN process).
    • Similarity testing using a tool referred to as “PA” to score whether a proposed name is too similar to existing ones.
    • Objection windows before a name becomes official.
  • Even brand names face heavy FDA constraints:
    • Proprietary names can’t be too similar to the generic name.
    • Proprietary names can’t reuse certain stems/suffixes from generic naming conventions.
    • Names can’t imply medical results or include problematic hints (like dosage-style numbers).
    • Names are checked again for similarity to existing brand/generic names.

Methodology / process presented (detailed)

A) Generic (ingredient) naming workflow (WHO + USAN)

  1. Propose naming targets while in development

    • As the drug enters the research/clinical phase, submit proposed names.

  2. Ensure the generic name meets structural rules

    • Generic names are typically built from:
      • A stem (indicates what the drug does; e.g., antifungal, antidepressant, antihistamine endings).
      • A prefix (often chosen primarily for uniqueness rather than meaning).
    • The name must also follow constraints such as:
      • Length limits: ideally short (the video notes generic names should have no more than five syllables, ideally two).
      • Letter restrictions: certain letters (e.g., H, K, J, W, Y) are not allowed because they may be silent or nonexistent in other languages.
      • No conflict with marketing/promotion intent: using a prefix that functions like a promotion is not acceptable; the generic name is in the public domain and must not operate as advertising.

  3. Run through formal similarity testing

    • The bodies use a PA tool to assess whether the proposed generic name is too similar to existing names.

  4. Publish and allow objections

    • If approved (e.g., low similarity score), the proposed name is added to a public list.
    • There is an objection period (the video mentions 4 months).

  5. Finalize the official generic name

    • After objections are handled, the name becomes the official INN/USAN-type generic identifier, usable worldwide.

B) Proprietary (brand) naming workflow (FDA)

  1. Try to generate candidate brand names

    • Brand naming is handled differently from generic naming (no WHO/USAN route).

  2. Apply proprietary-name restrictions

    • Must not:
      • Use more than three consecutive letters from the generic name.
      • Use generic stems (or other restricted overlaps).
      • Use certain suffix conventions that could imply route/type (the video uses “-po” as an example that historically could imply oral drugs).
      • Indicate route of administration or include medical abbreviations.
      • Be too similar in sound or appearance to existing names that could lead to prescribing/dispensing errors.
      • Include overly promissory or guaranteed effect language (e.g., “free 24/7”).
      • Include numbers (which could be mistaken for dosage or misheard/dropped).

  3. Similarity testing against existing drug names

    • As with generics, proprietary candidates are tested using a PA tool (the video mentions a threshold idea like “over 70%” similarity as a likely failure).

  4. Use a detailed phonetic/letter checklist

    • The video describes checks such as:
      • Same initial letter
      • Name length within a small tolerance (e.g., within two letters)
      • Letter shape strokes (upstrokes/downstrokes)
      • Specific “dog letters” (as a phonetic/visual category)
      • Infixes/suffixes
      • Syllable count and stress patterns
      • Vowel sound matches

  5. Decide whether the name is acceptable

    • If too similar or violating constraints, the candidate is rejected.
    • Otherwise, it can proceed toward approval.

Overall narrative (what the example is used to teach)

  • The video uses a humorous scenario: a fictional company creates a nasal decongestant that works only in the left nostril, then asks how to name it.
  • It demonstrates why a “normal person” can’t freely coin drug names:
    • Generic names require strict international structure and approval.
    • Brand names require additional FDA rules to avoid confusion, mispromises, and dangerous similarity.

Speakers / sources featured

  • “Half as Interesting” / the narrator-style host (implied by references to the channel and “crack team at Half as Interesting Pharmaceuticals”).
  • WHO (World Health Organization) (cited regarding lookalike/soundalike medication harms and the generic naming framework).
  • USAN Council (mentioned as the U.S. body adopting/handling American generic naming).
  • FDA (U.S. Food and Drug Administration) (mentioned as approving proprietary brand names).
  • Cool Earth (video sponsor; referenced as an organization protecting rainforests and funding indigenous communities).

Original video